the effect of intravenous administration of active recombinant factor vii on postoperative bleeding in cardiac valve reoperations; a randomized clinical trial

conclusions our study demonstrated the efficacy of rfviia in controlling postoperative bleeding in redo cardiac valve surgeries regarding subsequent blood loss and transfusion requirement; however, outcome results remains to be defined. results study groups showed no difference regarding baseline variables. three patients in rfviia group (16.67%) and 13 in placebo group (72.23%) received blood products (p < 0.01). chest tube blood drainage at 24th hour after operation was 315 ± 177 ml in rfviia group and 557 ± 168 ml in control group (p = 0.03). at third and 12th hour after operation, the difference was not statistically significant (p = 0.71 and p = 0.22, respectively). postoperative icu stay was not different; while extubation was longer in the placebo group (352 ± 57 vs. 287 ± 46 minutes; p = 0.003). objectives in a randomized double-blinded clinical trial of redo cardiac valve surgery in adult, the effect of active recombinant factor vii (rfviia) on postoperative bleeding was compared with placebo. chest tube drainage was used for comparison of bleeding between the two groups. patients and methods two groups of 18 patients undergoing redo valve surgeries were treated and compared regarding chest tube drainage, need for blood products, prothrombin time (pt), partial thromboplastin time (ptt), hemoglobin and hematocrit, platelet count, and international normalized ratio (inr) in first 24 hours after surgery. bleeding was assessed at 3rd, 12th, and 24th hour after operation. in rfviia group, 40 µg/kg of aryoseven was administered before end of surgery and same volume of normal saline was administered as placebo in the control group. background postoperative bleeding after cardiac reoperations is among the most complicating problems, both for the physicians and for the patients. many modalities have been used to decrease its adverse effects and the need for blood products administration.